Filgastrim: Difference between revisions
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | ||
|fdaLIADAdult=====Dosage==== | |fdaLIADAdult=====Dosage==== | ||
*The recommended dose of Filgastrim is 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose of Filgastrim no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer Filgastrim within 24 hours prior to chemotherapy. | *The recommended dose of Filgastrim is 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose of Filgastrim no earlier than 24 hours following [[myelosuppressive chemotherapy]]. Do not administer Filgastrim within 24 hours prior to [[chemotherapy]]. | ||
*Daily dosing with Filgastrim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Monitor complete blood count (CBC) prior to chemotherapy and twice per week until recovery. | *Daily dosing with Filgastrim should continue until the expected [[neutrophil]] nadir is passed and the [[neutrophil count]] has recovered to the normal range. Monitor complete blood count (CBC) prior to [[chemotherapy]] and twice per week until recovery. | ||
====General Considerations for Administration==== | ====General Considerations for Administration==== | ||
| Line 61: | Line 61: | ||
|clinicalTrials='''Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.''' | |clinicalTrials='''Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.''' | ||
Filgastrim clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for [[breast cancer]] (N=348), [[lung cancer]] (N=240) and [[non-Hodgkin’s lymphoma]] (N=92). In the [[breast cancer]] study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the [[lung cancer]] study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the non-Hodgkin’s lymphoma study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a [[placebo]] (Cycle 1 of the [[breast cancer]] study only) or a non-US-approved filgrastim product were used as controls. Both Filgastrim and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an [[ANC]] of ≥10,000 x 106/L after nadir was reached. | *Filgastrim clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for [[breast cancer]] (N=348), [[lung cancer]] (N=240) and [[non-Hodgkin’s lymphoma]] (N=92). In the [[breast cancer]] study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the [[lung cancer]] study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the [[non-Hodgkin’s lymphoma]] study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a [[placebo]] (Cycle 1 of the [[breast cancer]] study only) or a non-US-approved filgrastim product were used as controls. Both Filgastrim and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an [[ANC]] of ≥10,000 x 106/L after nadir was reached. | ||
[[Bone pain]] was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with Filgastrim at the recommended dose and was numerically two times more frequent than in the placebo group. Theoverall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% Filgastrim, 1.4% placebo, 7.5% non-US-approved filgrastim product). | [[Bone pain]] was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with Filgastrim at the recommended dose and was numerically two times more frequent than in the placebo group. Theoverall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% Filgastrim, 1.4% placebo, 7.5% non-US-approved filgrastim product). | ||
=====Leukocytosis===== | =====Leukocytosis===== | ||
*In clinical studies, [[leukocytosis]] (WBC counts > 100,000 x 106/L) was observed in less than 1% patients with non-myeloid malignancies receiving Filgastrim No complications attributable to leukocytosis were reported in clinical studies. | *In clinical studies, [[leukocytosis]] (WBC counts > 100,000 x 106/L) was observed in less than 1% patients with [[non-myeloid malignancies]] receiving Filgastrim No complications attributable to [[leukocytosis]] were reported in clinical studies. | ||
=====Additional Adverse Reactions===== | =====Additional Adverse Reactions===== | ||
*Other adverse reactions known to occur following administration of human [[granulocyte colony-stimulating factors]] include [[myalgia]], [[headache]], [[vomiting]], [[Sweet’s syndrome]] (acute [[febrile neutrophilic dermatosis]]), [[cutaneous vasculitis]] and [[thrombocytopenia]]. | *Other adverse reactions known to occur following administration of human [[granulocyte colony-stimulating factors]] include [[myalgia]], [[headache]], [[vomiting]], [[Sweet’s syndrome]] (acute [[febrile neutrophilic dermatosis]]), [[cutaneous vasculitis]] and [[thrombocytopenia]]. | ||
|drugInteractions=*No formal drug interaction studies between Filgastrim and other drugs have been performed. | |drugInteractions=*No formal drug interaction studies between Filgastrim and other drugs have been performed. | ||
*Drugs which may potentiate the release of | *Drugs which may potentiate the release of [[neutrophils]]‚ such as [[lithium]]‚ should be used with caution. | ||
*Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone-imaging results. | *Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone-imaging results. | ||
|FDAPregCat=C | |FDAPregCat=C | ||
| Line 81: | Line 81: | ||
|useInHepaticImpair=The safety and efficacy of Filgastrim have not been studied in patients with hepatic impairment. | |useInHepaticImpair=The safety and efficacy of Filgastrim have not been studied in patients with hepatic impairment. | ||
|overdose=*No case of overdose has been reported. | |overdose=*No case of overdose has been reported. | ||
|mechAction=*Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity. | |mechAction=*Tbo-filgrastim is a human [[granulocyte colony-stimulating factor]] ([[G-CSF]]) produced by recombinant [[DNA]] technology. Tbo-filgrastim binds to [[G-CSF]] receptors and stimulates proliferation of [[neutrophils]]. [[G-CSF]] is known to stimulate differentiation commitment and some end-cell functional activation, which increases [[neutrophil counts]] and activity. | ||
|PD=*In the clinical trials of patients with cancer, the time to the ANCmax was between 3 to 5 days and returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16%-19% increase in the ANCmax and a 33%-36% increase in the area under the effect curve for ANC. | |PD=*In the clinical trials of patients with cancer, the time to the ANCmax was between 3 to 5 days and returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16%-19% increase in the ANCmax and a 33%-36% increase in the area under the effect curve for ANC. | ||
<br> | <br> | ||
Revision as of 17:34, 11 February 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Filgastrim is a colony stimulating factor that is FDA approved for the treatment of severe neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia. Common adverse reactions include bone pain.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Dosage
- The recommended dose of Filgastrim is 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose of Filgastrim no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer Filgastrim within 24 hours prior to chemotherapy.
- Daily dosing with Filgastrim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Monitor complete blood count (CBC) prior to chemotherapy and twice per week until recovery.
General Considerations for Administration
- Filgastrim may be administered by either a healthcare professional or by a patient or caregiver. Before a decision is made to allow Filgastrim to be administered by a patient or caregiver, ensure that the patient is an appropriate candidate for self-administration or administration by a caregiver. Proper training on storage, preparation, and administration technique should be provided. If a patient or caregiver is not an appropriate candidate for any reason, then in such patients, Filgastrim should be administered by a healthcare professional.
- Dispense only the pre-filled syringe without a safety needle guard device to patient or caregiver. Instruct patients and caregivers to follow the Instructions for Use provided with the Filgastrim pre-filled syringe to properly administer an injection after training by a healthcare professional.
- Visually inspect parenteral drug products for particulate matter and discoloration prior to administration.
- Do not administer Filgastrim if discoloration or particulates are observed.
- The prefilled syringe is for single use only. Discard unused portions.
- Recommended sites for subcutaneous Filgastrim injections include the abdomen (except for the two-inch area around the navel), the front of the middle thighs, the upper outer areas of the buttocks, or the upper back portion of the upper arms. The injection site should be varied daily. Filgastrim should not be injected into an area that is tender, red, bruised or hard, or that has scars or stretch marks.
Instructions for Use of the Safety Needle Guard Device by Healthcare Professionals
Hold the syringe assembly by the open sides of the device and remove the needle shield.
- Step Nº1:
- Step Nº2:
- Step Nº3:
- Step Nº4:
- Step Nº5:
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Filgastrim in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Filgastrim in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Filgastrim FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Filgastrim in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Filgastrim in pediatric patients.
Contraindications
None
Warnings
Splenic Rupture
- Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors. In patients who report upper abdominal or shoulder pain after receiving Filgastrim, discontinue Filgastrim and evaluate for an enlarged spleen or splenic rupture.
Acute Respiratory Distress Syndrome (ARDS)
- Acute respiratory distress syndrome (ARDS) can occur in patients receiving human granulocyte colony-stimulating factors. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Filgastrim, for ARDS. Discontinue Filgastrim in patients with ARDS.
Allergic Reactions
- Serious allergic reactions including anaphylaxis can occur in patients receiving human granulocyte colony-stimulating factors. Reactions can occur on initial exposure. The administration of antihistamines‚ steroids‚ bronchodilators‚ and/or epinephrine may reduce the severity of the reactions. Permanently discontinue Filgastrim in patients with serious allergic reactions. Do not administer Filgastrim to patients with a history of serious allergic reactions to filgrastim or pegfilgrastim.
Use in Patients with Sickle Cell Disease
- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving human granulocyte colony-stimulating factors. Consider the potential risks and benefits prior to the administration of human granulocyte colony-stimulating factors in patients with sickle cell disease. Discontinue Filgastrim in patients undergoing a sickle cell crisis.
Capillary Leak Syndrome
- Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
- The granulocyte colony-stimulating factor (G‑CSF) receptor through which Filgastrim acts has been found on tumor cell lines. The possibility that Filgastrim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which Filgastrim is not approved, cannot be excluded.
Adverse Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
- Filgastrim clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for breast cancer (N=348), lung cancer (N=240) and non-Hodgkin’s lymphoma (N=92). In the breast cancer study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the lung cancer study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the non-Hodgkin’s lymphoma study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a placebo (Cycle 1 of the breast cancer study only) or a non-US-approved filgrastim product were used as controls. Both Filgastrim and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 106/L after nadir was reached.
Bone pain was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with Filgastrim at the recommended dose and was numerically two times more frequent than in the placebo group. Theoverall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% Filgastrim, 1.4% placebo, 7.5% non-US-approved filgrastim product).
Leukocytosis
- In clinical studies, leukocytosis (WBC counts > 100,000 x 106/L) was observed in less than 1% patients with non-myeloid malignancies receiving Filgastrim No complications attributable to leukocytosis were reported in clinical studies.
Additional Adverse Reactions
- Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet’s syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.
Postmarketing Experience
There is limited information regarding Filgastrim Postmarketing Experience in the drug label.
Drug Interactions
- No formal drug interaction studies between Filgastrim and other drugs have been performed.
- Drugs which may potentiate the release of neutrophils‚ such as lithium‚ should be used with caution.
- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone-imaging results.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): C
There are no adequate and well-controlled studies of Filgastrim in pregnant women. In animal reproduction studies, treatment of pregnant rabbits with tbo-filgrastim resulted in increased spontaneous abortion and fetal malformations at systemic exposures substantially higher than the human exposure. Filgastrim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Filgastrim in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Filgastrim during labor and delivery.
Nursing Mothers
It is not known whether tbo-filgrastim is secreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Filgastrim is administered to a nursing woman. Other recombinant G-CSF products are poorly secreted in breast milk and G-CSF is not orally absorbed by neonates.
Pediatric Use
The safety and effectiveness of Filgastrim in pediatric patients have not been established.
Geriatic Use
Among 677 cancer patients enrolled in clinical trials of Filgastrim a total of 111 patients were 65 years of age and older. No overall differences in safety or effectiveness were observed between patients age 65 and older and younger patients.
Gender
There is no FDA guidance on the use of Filgastrim with respect to specific gender populations.
Race
There is no FDA guidance on the use of Filgastrim with respect to specific racial populations.
Renal Impairment
The safety and efficacy of Filgastrim have not been studied in patients with moderate or severe renal impairment. No dose adjustment is recommended for patients with mild renal impairment.
Hepatic Impairment
The safety and efficacy of Filgastrim have not been studied in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Filgastrim in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Filgastrim in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Filgastrim Administration in the drug label.
Monitoring
There is limited information regarding Filgastrim Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Filgastrim and IV administrations.
Overdosage
- No case of overdose has been reported.
Pharmacology
There is limited information regarding Filgastrim Pharmacology in the drug label.
Mechanism of Action
- Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.
Structure
There is limited information regarding Filgastrim Structure in the drug label.
Pharmacodynamics
- In the clinical trials of patients with cancer, the time to the ANCmax was between 3 to 5 days and returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16%-19% increase in the ANCmax and a 33%-36% increase in the area under the effect curve for ANC.
Cardiac Electrophysiology: At the maximum recommended intravenous dose of 5 μg/kg, tbo-filgrastim did not prolong the QT interval to any clinically relevant extent.
Pharmacokinetics
- In healthy subjects, the absolute bioavailability of 5 mcg/kg subcutaneous tbo-filgrastim was 33%. Increasing the dose of tbo-filgrastim from 5 to 10 mcg/kg in these healthy subjects resulted in an approximately 200% increase in both the maximum concentration (Cmax) and the area under the curve (AUC0-48h) of the drug.
- In the clinical trials of patients with cancer, the AUC and Cmax were greater and more variable compared to healthy volunteers receiving the same dose of tbo-filgrastim subcutaneously. The median time to maximum concentration was between 4 to 6 hours and the median elimination half-life was between 3.2 to 3.8 hours. Accumulation was not observed after repeated dosing.
Pharmacokinetics in Specific Populations
- Age: Not evaluated.
- Gender: No gender-related differences were observed.
- Renal Impairment: Mild renal impairment (creatinine clearance 60 - 89 mL/min) had no effect on tbo-filgrastim pharmacokinetics (N=11). The pharmacokinetic profile in patients with moderate and severe renal impairment has not been assessed.
- Hepatic Impairment: The pharmacokinetic profile in patients with hepatic impairment has not been assessed.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
- Carcinogenicity and genetic toxicology studies have not been conducted with tbo-filgrastim.
- A fertility study was not conducted with tbo-filgrastim. Toxicology studies of up to 26 weeks in rats or monkeys did not reveal findings in male or female reproductive organs that would suggest impairment of fertility.
Clinical Studies
- The efficacy of Filgastrim was evaluated in a multinational, multicenter, randomized and controlled Phase 3 study in 348 chemotherapy-naive patients with high-risk stage II, stage III, or stage IV breast cancer receiving doxorubicin (60 mg/m2) and docetaxel (75 mg/m2) comparing Filgastrim to placebo and a non-US-approved filgrastim product as controls. The median age of the patients was 50 years (range 25 to 75 years) with 99% female and 86% Caucasian.
- Filgastrim, placebo, and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 106/L after nadir was reached.
- Filgastrim was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001).
How Supplied
Filgastrim 300 mcg/0.5 mL: Each prefilled syringe contains 300 mcg of tbo-filgrastim in 0.5 mL solution with a blue plunger in:
- Pack of 1 with a safety needle guard in blister: NDC 63459-910-11
- Packs of 10 with a safety needle guard in blisters: NDC 63459-910-15
- Pack of 1 without a safety needle guard (for patients and caregivers): NDC 63459-910-17
- Packs of 5 without a safety needle guard (for patients and caregivers): NDC 63459-910-36
Filgastrim 480 mcg/0.8 mL: Each prefilled syringe contains 480 mcg of tbo-filgrastim in 0.8 mL solution with a clear plunger in:
- Pack of 1 with a safety needle guard in blister: NDC 63459-912-11
- Packs of 10 with a safety needle guard in blisters: NDC 63459-912-15
- Pack of 1 without a safety needle guard (for patients and caregivers): NDC 63459-912-17
- Packs of 5 without a safety needle guard (for patients and caregivers): NDC 63459-912-36
Storage
Filgastrim syringes should be stored in a refrigerator at 36° to 46° F (2° to 8° C). Protect from light. Within its shelf life, the product may be removed from 36° to 46° F (2° to 8° C) storage for a single period of up to 5 days between 73° to 81° F (23° to 27° C). If not used within 5 days, the product may be returned to 36° to 46° F (2° to 8° C) up to the expiration date.
Images
Drug Images
{{#ask: Page Name::Filgastrim |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Filgastrim |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Filgastrim Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Filgastrim interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Look-Alike Drug Names
There is limited information regarding Filgastrim Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.